Seth Boese

Seth Boese currently serves as the Chief Operating Officer and Chief Technical Officer at 3iBiotechnologies, where he plays a pivotal role in steering the company's strategic direction and technological innovation. With a deep expertise in drug development and delivery methodologies, Seth is at the forefront of pioneering solutions that address critical challenges in post-operative bariatric care and immunomodulation systems. His leadership is instrumental in advancing the company's portfolio of novel drug delivery platforms, including cutting-edge microneedle arrays and floss-based systems, designed to optimize therapeutic efficacy while significantly reducing medication costs.

In his dual executive roles, Seth oversees the development of innovative delivery systems that leverage advanced chemistry, cell culture techniques, and high-performance liquid chromatography (HPLC) to ensure quality and consistency. His strategic focus on research and product development enables 3iBiotechnologies to stay ahead of industry trends, fostering strategic partnerships that accelerate the commercialization of breakthrough treatments. Seth’s expertise in statistics and data analysis informs evidence-based decision-making, ensuring that new systems are both safe and effective.

Moreover, Seth’s leadership extends to guiding multidisciplinary teams through complex research initiatives, emphasizing the importance of communication and collaboration in translating scientific insights into market-ready solutions. His commitment to improving patient outcomes through minimally invasive, cost-effective drug delivery platforms underscores his dedication to innovation in biopharmaceuticals. By integrating his skills in strategy, chemistry, and research, Seth Boese continues to position 3iBiotechnologies as a leader in next-generation therapeutic systems, ultimately transforming post-operative care and immunomodulation therapies.